Work

Abstract A142: Risk of dermatologic adverse events with Amivantamab in EGFR-mutant non-small cell lung cancer: A meta-analysis of phase III trials

Year: 2025

Type: review

Study designs: Systematic Review, Meta-Analysis

Source: Molecular Cancer Therapeutics

DOI: 10.1158/1535-7163.targ-25-a142

Authors: Jason Ta, Abbas Hussain, Riccesha Hattin, Daniel T. Jones, Ramaditya Srinivasmurthy, Rishi K. Nanda, Clinton Lam, Kyaw Z. Thein

Institutions: University of South Florida, HCA Healthcare, University of Nevada, Las Vegas, Icahn School of Medicine at Mount Sinai, Touro University Nevada, Comprehensive Cancer Centers of Nevada

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4415444703

FWCI:

Cites:

Cited by:

Related to: